

Michael Bitzer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4532644/publications.pdf>

Version: 2024-02-01

27
papers

1,844
citations

567281

15
h-index

552781

26
g-index

27
all docs

27
docs citations

27
times ranked

2841
citing authors

#	ARTICLE	IF	CITATIONS
1	Swarm Learning for decentralized and confidential clinical machine learning. <i>Nature</i> , 2021, 594, 265-270.	27.8	375
2	Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 803-815.	8.1	205
3	Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial. <i>European Journal of Cancer</i> , 2017, 81, 183-190.	2.8	197
4	<i>NRG1</i> Fusions in <i>KRAS</i> Wild-Type Pancreatic Cancer. <i>Cancer Discovery</i> , 2018, 8, 1087-1095.	9.4	189
5	Antibody-induced procoagulant platelets in severe COVID-19 infection. <i>Blood</i> , 2021, 137, 1061-1071.	1.4	162
6	Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFTY score. <i>Journal of Hepatology</i> , 2022, 76, 353-363.	3.7	132
7	Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma – The SHELTER study. <i>Journal of Hepatology</i> , 2016, 65, 280-288.	3.7	98
8	Plants Release Precursors of Histone Deacetylase Inhibitors to Suppress Growth of Competitors. <i>Plant Cell</i> , 2015, 27, 3175-3189.	6.6	86
9	Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia. <i>Immunity</i> , 2021, 54, 1578-1593.e5.	14.3	75
10	Cellular senescence in gastrointestinal diseases: from pathogenesis to therapeutics. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 81-95.	17.8	62
11	Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 3830.	3.7	47
12	Electronic Patient-Reported Outcome Measures in Radiation Oncology: Initial Experience After Workflow Implementation. <i>JMIR MHealth and UHealth</i> , 2019, 7, e12345.	3.7	37
13	Severe SARS-CoV-2 Infection Inhibits Fibrinolysis Leading to Changes in Viscoelastic Properties of Blood Clot: A Descriptive Study of Fibrinolysis in COVID-19. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1417-1426.	3.4	32
14	Trailblazing precision medicine in Europe: A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany. <i>Seminars in Cancer Biology</i> , 2022, 84, 242-254.	9.6	22
15	Upregulation of cAMP prevents antibody-mediated thrombus formation in COVID-19. <i>Blood Advances</i> , 2022, 6, 248-258.	5.2	19
16	A data management infrastructure for the integration of imaging and omics data in life sciences. <i>BMC Bioinformatics</i> , 2022, 23, 61.	2.6	18
17	Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment Options. <i>JCO Precision Oncology</i> , 2020, 4, 258-271.	3.0	16
18	Deep regional hyperthermia with preoperative radiochemotherapy in locally advanced rectal cancer, a prospective phase II trial. <i>Radiotherapy and Oncology</i> , 2021, 159, 155-160.	0.6	16

#	ARTICLE	IF	CITATIONS
19	Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol. <i>Future Oncology</i> , 2022, 18, 1423-1435.	2.4	14
20	Antibody Binding and Angiotensin-Converting Enzyme 2 Binding Inhibition Is Significantly Reduced for Both the BA.1 and BA.2 Omicron Variants. <i>Clinical Infectious Diseases</i> , 2023, 76, e240-e249.	5.8	11
21	Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinoma. <i>Npj Precision Oncology</i> , 2021, 5, 80.	5.4	10
22	Predictive performance of the mHAP-II score in a real-life western cohort with hepatocellular carcinoma following trans-arterial chemoembolisation with drug-eluting beads (DEB-TACE). <i>European Radiology</i> , 2020, 30, 3782-3792.	4.5	9
23	Efficacy and tolerability of chemosaturation in patients with hepatic metastases from uveal melanoma. <i>Acta Radiologica</i> , 2021, , 028418512110198.	1.1	5
24	Intraprocedural cone-beam CT with parenchymal blood volume assessment for transarterial chemoembolization guidance: Impact on the effectiveness of the individual TACE sessions compared to DSA guidance alone. <i>European Journal of Radiology</i> , 2021, 140, 109768.	2.6	3
25	Correlation between acoustic radiation force impulse (ARFI)-based tissue elasticity measurements and perfusion parameters acquired by perfusion CT in cirrhotic livers: a proof of principle. <i>Journal of Medical Ultrasonics (2001)</i> , 2019, 46, 81-88.	1.3	2
26	CT hepatic arterial perfusion index does not allow stratification of the degree of esophageal varices and bleeding risk in cirrhotic patients in Child-Pugh classes A and B. <i>Abdominal Radiology</i> , 2021, 46, 5586-5597.	2.1	2
27	Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: The DEMAND randomized phase II clinical trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS492-TPS492.	1.6	0